Business, energy, technology, markets and global industry news from Business News Today

Dupilumab

PharmaDeviceNews Dupilumab
Representative image of an atopic dermatitis drug development concept, illustrating how Zai Lab’s ZL-1503 is being positioned to target itch and inflammation pathways in early-stage immunology research.
Pharma & Biotech

Can Zai Lab’s ZL-1503 turn dual-pathway itch control into a real atopic dermatitis advantage?

Zai Lab’s ZL-1503 showed durable preclinical itch and inflammation control. Read what its 2026 clinical path could mean for atopic dermatitis.

Read More
Representative image of a child undergoing a dermatology skin examination, illustrating the growing focus on pediatric eczema treatment as Galderma’s nemolizumab phase II data sharpen competition in the biologic landscape for atopic dermatitis.
Pharma & Biotech

What Galderma’s nemolizumab phase II data mean for the competitive biologic landscape in pediatric eczema

Galderma's nemolizumab phase II data in children aged 2-11 show 52-week itch and lesion relief. Read the analysis.

Read More
Pharma & Biotech

Can Regeneron Pharmaceuticals redefine allergy treatment with Phase 3 allergen-blocking antibodies and Dupilumab expansion

Find out how Regeneron Pharmaceuticals’ AAAAI 2026 data could reshape allergy treatment strategies and regulatory expectations.

Read More